Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
|Articles|July 15, 2008
OPTIMIZING ADJUNCTIVE IOP-LOWERING THERAPY: Rationale and Benefits for Prescribing Istalol®
Ideally, control of elevated IOP in patients with ocular hypertension or glaucoma might be achieved with monotherapy. However, published data indicate that treatment with a single modality is often not enough. In the Ocular Hypertension Treatment Study, which enrolled a generally healthy cohort and set a relatively modest therapeutic goal of a ?20% IOP reduction, 40% of patients needed 2 medications and 10% required 3 medications to reach this goal. These results are consistent with those in other publications and my clinical experience.
Advertisement
Advertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement